Licochalcone E reduces chronic allergic contact dermatitis and inhibits IL-12p40 production through down-regulation of NF-kappa B.
Int Immunopharmacol, 2010/9;10(9):1119-26.
Cho YC[1], Lee SH, Yoon G, Kim HS, Na JY, Choi HJ, Cho CW, Cheon SH, Kang BY
Affiliations
PMID: 20601178DOI: 10.1016/j.intimp.2010.06.015
Impact factor: 5.714
Abstract
Licochalcone, a constituent of licorice, has antitumor, antimicrobial, and anti-inflammatory effects. Recently, licochalcone E was isolated from the roots of Glycyrrhiza inflata and its biological functions are not fully examined. In this study, we investigated its ability to modulate production of IL-12p40, a common subunit of IL-12 and IL-23. Licochalcone E dose-dependently inhibited IL-12p40 production from lipopolysaccharide-stimulated RAW264.7 macrophage cells. The repressive effect was mapped to a region in the IL-12 gene promoter containing a binding site for NF-kappaB. Furthermore, licochalcone E decreased binding to the NF-kappaB site in RAW264.7 macrophage cells. Using a chronic allergic contact dermatitis model induced by repeated application of oxazolone, we showed that licochalcone E inhibited the increased IL-12p40 expression and ear thickness induced by oxazolone. Taken together, licochalcone E inhibits IL-12p40 production and has therapeutic potential to reduce skin inflammation.
MeSH terms
Animals; Anti-Inflammatory Agents; Cells, Cultured; Chalcones; Chronic Disease; Dermatitis, Allergic Contact; Down-Regulation; Female; Interleukin-12 Subunit p40; Macrophages; Mice; Mice, Inbred C57BL; NF-kappa B; Oxazolone; Promoter Regions, Genetic
More resources
EndNote: Download